<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379080</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00681</org_study_id>
    <secondary_id>NCI-2009-00681</secondary_id>
    <secondary_id>CDR0000495253</secondary_id>
    <secondary_id>NABTT 0504</secondary_id>
    <secondary_id>NABTT-0504</secondary_id>
    <secondary_id>U01CA137443</secondary_id>
    <nct_id>NCT00379080</nct_id>
  </id_info>
  <brief_title>Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma</brief_title>
  <official_title>A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and best dose of tandutinib and to see how
      well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
      blocking blood flow to the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the ability of tandutinib to achieve a target tumor/plasma ratio â‰¥ 0.33 in patients
      with recurrent glioblastoma undergoing resection. (Feasibility study) II. Detect potential
      biological effects of tandutinib by measuring platelet-derived growth factor receptor
      phosphorylation status and downstream activation of Akt and Erk. (Feasibility study) III.
      Determine the maximum tolerated dose of tandutinib in patients with recurrent or progressive
      glioblastoma. (Phase I) IV. Estimate the frequency of toxicities associated with tandutinib
      in patients with recurrent or progressive glioblastoma. (Phase I) V. Describe the
      pharmacokinetics of this route of administration in patients with recurrent or progressive
      glioblastoma. (Phase I) VI. Assess tumor response rate in patients with recurrent or
      progressive glioblastoma. (Phase II)

      SECONDARY OBJECTIVES:

      I. Estimate overall survival of patients with recurrent or progressive glioblastoma. (Phase
      II) II. Estimate the 6-month progression-free survival rate in these patients. (Phase II)
      III. Assess the toxicities associated with tandutinib in these patients. (Phase II) IV.
      Assess the pharmacokinetic profile of this route of administration in these patients. (Phase
      II) V. Explore protein-expression patterns that distinguish patients who respond to therapy
      from those who do not. (Phase II)

      OUTLINE: This is a multicenter, prospective, nonrandomized, feasibility study and phase I
      study (in parallel) followed by an open label phase II study.

      FEASIBILITY STUDY: Patients receive oral tandutinib twice daily for 7 days. Patients then
      undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery,
      patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in
      the absence of disease progression or unacceptable toxicity.

      PHASE I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28
      days in the absence of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
      of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.

      [Note: *On day 1 of course 1, patients receive only 1 dose of tandutinib.]

      PHASE II: Patients receive tandutinib as in phase I at the MTD determined in phase I.

      Patients undergo blood sample collection for pharmacokinetic studies. Patients in the
      feasibility portion of the study also undergo blood and tissue sample collection for
      correlative studies by mass spectrometry for tandutinib concentration. Samples are also
      examined for circulating endothelial cells and plasma proteins (vascular endothelial growth
      factor [VEGF]-A, -B, -C, and -D, soluble VEGF receptors [sVEGFR's], placental growth factor
      [P1GF], platelet-derived growth factor [PDGF]-AA, PDGF-AB, PDGF-BB, angiopoietin-1 and -2,
      tumstatin, thrombospondin-1, and IL-8) as potential markers of the antiangiogenic effect of
      tandutinib.

      After completion of study treatment, patients are followed every 2 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities (Phase 1)</measure>
    <time_frame>cycle 1 - 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To Determine the Tumor/Plasma Ratio of in Subjects With Recurrent GBM Undergoing Resections (Phase 0)</measure>
    <time_frame>7 days prior to surgery including surgery</time_frame>
    <description>participants are administered tandutinib (500mg BID) for 7 days prior to surgery and then undergo resection for recurrent glioblastoma. Tissue samples will be collected for correlative studies - determine tumor/plasma ratio.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities Per Dose Level</measure>
    <time_frame>28 days</time_frame>
    <description>cohorts of 3-6 pts will recieve oral tandutinib starting at 500mg BID with a dose escalation in each cohort. Each treatment cycle is 28 days. Evaluation period for MTD is 1st cycle - 28 days.
dose limiting toxicity defined as: grades 3-4 severity (except vomiting and diarrhea without sufficient prophylaxis delay of treatment &gt; 14 days. ANC less/equal 500m/mm3; Plts less/equal 25,000/mm3; febrile neutropenia or delay of treatment &gt; 14 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Response (Complete Response and Partial Response) Rate (Phase II)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>pts receive a scan baseline and prior to every odd cycle. All responses are centrally reviewed Complete response Complete disappearance of all tumor on MRI scan, off all glucocorticoids with stable or improving neurological exam minimum of 4 wks Partial response Greater than or equal 50% reduction in tumor size on MRI, on sable or decreasing glucocorticoids with stable or improving neurological exam for a minimum of 4 wks.
Progressive disease Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.
Stable disease Clinical status and MRI does not qualify for complete response, partial response or progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Max Concentration of Plasma) for Tandutinib in Phase 1 and Phase 2</measure>
    <time_frame>28 days</time_frame>
    <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Apparent Terminal Phase Half-life) for Tandutinib in Phase 1 and Phase 2</measure>
    <time_frame>28 days</time_frame>
    <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Area Under the Plasma Concentration Time Profile From Zero to Infinity (AUC)) for Tandutinib in Phase 1 and Phase 2</measure>
    <time_frame>28 days</time_frame>
    <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics; Apparent Oral Clearance for Tandutinib in Phase 1 and Phase 2</measure>
    <time_frame>28 days</time_frame>
    <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics; Apparent Oral Total Body Volume of Distribution for Tandutinib in Phase 1 and Phase 2</measure>
    <time_frame>28 days</time_frame>
    <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics; Steady-state Trough Concentration for Tandutinib in Phase 1 and Phase 2</measure>
    <time_frame>28 days</time_frame>
    <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Phase II)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Median time of survival along with 95% confidence interval will be estimated using Kaplan-Meier method. An overall failure rate will be estimated with 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-month Progression-free Survival Rate (Phase II)</measure>
    <time_frame>At 6 months</time_frame>
    <description>The probability of 6-momth progression-free survival will be estimated using binomial distribution.
Progression defined as: Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Failure Rate (Phase II)</measure>
    <time_frame>up to 4 years</time_frame>
    <description>The overall failure rate is expressed as hazard of failure per person-year of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Serious or Life Threatening Toxicities</measure>
    <time_frame>2 year period</time_frame>
    <description>Grade 3 or 4 toxicities related to treatment as determined by the CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein Expression Patterns Post Treatment - Loss or Gain</measure>
    <time_frame>baseline - cycle 2 (28 days)</time_frame>
    <description>serial blood samples over multiple time points (prior to treatment, 2 days post treatment, 8 days post treatment, 10 days post treatment and 28 days post treatment.
statistical analyses presented for the comparisons that yielded a p-value &lt;=0.05</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Adult Brain Tumor</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Arm I - Feasibility</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
conventional surgery
oral tandutinib
Pharmacological study
Tissue samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Dose Escalation (Phase 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
the starting dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - Phase 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm I - Feasibility</arm_group_label>
    <other_name>MLN518</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tandutinib</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I - Feasibility</arm_group_label>
    <arm_group_label>Arm 2 - Dose Escalation (Phase 1)</arm_group_label>
    <arm_group_label>Arm 3 - Phase 2</arm_group_label>
    <other_name>CT53518</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I - Feasibility</arm_group_label>
    <arm_group_label>Arm 2 - Dose Escalation (Phase 1)</arm_group_label>
    <arm_group_label>Arm 3 - Phase 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tissue samples</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I - Feasibility</arm_group_label>
    <arm_group_label>Arm 2 - Dose Escalation (Phase 1)</arm_group_label>
    <arm_group_label>Arm 3 - Phase 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:

          -  Histologically confirmed glioblastoma:

               -  Progressive or recurrent disease after prior radiotherapy (with or without
                  chemotherapy)

               -  Patients with a previous low-grade glioma that progressed after prior
                  radiotherapy (with or without chemotherapy) and are found to have glioblastoma by
                  biopsy are eligible

          -  Measurable disease, defined as contrast-enhancing progressive or recurrent
             glioblastoma by MRI or CT imaging within the past 2 weeks

          -  Must be maintained on a stable corticosteroid regimen from the time of baseline scan
             to the start of study treatment

          -  Feasibility study only:

               -  Planning to undergo surgical resection or biopsy

               -  Stereotactic biopsy for confirmation of tumor progression or differentiation of
                  tumor progression from treatment-induced effects allowed

               -  Corticosteroids must be tapered to the lowest required steroid dose and patient
                  must be maintained on a stable dose after surgery or biopsy

          -  Karnofsky performance status 60-100%

          -  Absolute neutrophil count &gt;= 1,500/mm^3

          -  Hemoglobin &gt;= 10 mg/dL

          -  Bilirubin =&lt; 1.5 mg/dL

          -  AST and ALT =&lt; 4 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier method contraception during and for 3
             months after completion of study treatment

          -  Mini Mental State Exam score &gt;= 15

          -  Mean QTc =&lt; 500 msec (with Bazett's correction) by screening electrocardiogram

          -  LVEF &gt;= 40%

          -  No history of familial long QT syndrome

          -  No myocardial infarction within the past 6 months

          -  No severe uncontrolled ventricular arrhythmias

          -  No uncontrolled angina

          -  No electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities

          -  No ongoing vomiting or nausea &gt;= grade 2

          -  No gastrointestinal tract disease resulting in an inability to take oral medication or
             a requirement for intravenous alimentation

          -  No active peptic ulcer disease

          -  No other condition that would impair ability to swallow pills or absorb oral
             medications

          -  No muscular dystrophy

          -  No myasthenia gravis

          -  No other known or suspected primary muscular or neuromuscular disease

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to tandutinib (e.g., erlotinib hydrochloride, gefetinib, or
             doxazosin mesylate)

          -  Patients who developed an acneiform/maculopustular rash while receiving either
             gefitinib or erlotinib hydrochloride are eligible unless the rash is considered an
             allergic reaction (angioedema/urticaria) or Stevens-Johnson syndrome

          -  No ongoing or active infections

          -  No psychiatric illness or social situations that would preclude study compliance

          -  No other serious infection or medical illness

          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)

          -  No other uncontrolled illness

          -  No other malignancy within the past 5 years except for basal cell or squamous cell
             skin cancer or carcinoma in situ of the cervix or breast

          -  Recovered from prior therapy

          -  At least 3 months since prior radiotherapy

          -  No prior surgical procedures affecting absorption

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational agents

          -  No concurrent agent that would cause QTc prolongation

          -  No concurrent prophylactic growth factors (e.g., filgrastim [G-CSF] or sargramostim
             [GM-CSF])

          -  At least 10 days since prior and no concurrent anticonvulsant drugs that induce
             hepatic metabolic enzymes (e.g., primidone, oxcarbazepine, phenytoin, carbamazepine,
             or phenobarbital)

          -  No prior treatment with small molecule inhibitors of platelet-derived growth factor
             receptor (e.g., sunitinib malate, sorafenib, or imatinib mesylate)

          -  Platelet count &gt;= 100,000/mm^3

          -  No New York Heart Association class III or IV heart failure

          -  Creatinine =&lt; 1.5 mg/dL OR creatinine clearance &gt;= 60mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy Batchelor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <results_first_submitted>July 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2017</results_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients enrolled from 4/2007 through 6/2010. Patients accrued in the outpatient clinical setting. The first part of study was for patients who required surgery. Hence these patients were treated in-patient.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1- Phase 0</title>
          <description>Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
conventional surgery
oral tandutinib
Pharmacological study
Tissue samples</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 - Phase 1</title>
          <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
tandutinib: Given orally
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="P3">
          <title>Arm 3 - Phase 2</title>
          <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>all pts had to have confirmed histological GBM, prior treatment wih RT and a MMSE of greater or equal to 15.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1 - Phase 0</title>
          <description>Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
conventional surgery
oral tandutinib
Pharmacological study
Tissue samples</description>
        </group>
        <group group_id="B2">
          <title>Arm 2 - Phase 1</title>
          <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
tandutinib: Given orally
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="B3">
          <title>Arm 3 - Phase 2</title>
          <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="48" upper_limit="72"/>
                    <measurement group_id="B2" value="56" lower_limit="42" upper_limit="77"/>
                    <measurement group_id="B3" value="54" lower_limit="24" upper_limit="69"/>
                    <measurement group_id="B4" value="56" lower_limit="24" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status</title>
          <description>Higher score better 100 normal no complaints/disease 90 capable normal activity few symptoms/disease 80 normal activity, some difficulty some symptoms/signs 70 caring for self not capable normal activity/work 60 requiring some help can take care of most personal requirements 50 requires help often requires frequent medical care 40 disabled requires special care/help 30 severely disabled hospital admission indicated but no risk of death 20 very ill urgently requiring admission requires supportive measures/treatment 10 moribund rapidly progressive fatal disease processes 0 death</description>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B2" value="90" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B3" value="90" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="B4" value="90" lower_limit="60" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental Score</title>
          <description>The miniâ€“mental state examination (MMSE) is a 30-point questionnaire test used to screen for cognitive impairment. Commonly used to screen for dementia. It is also used to estimate the severity of cognitive impairment and to follow the course of cognitive changes in an individual over time. The MMSE test includes simple questions and problems in a number of areas: the time and place of the test, repeating lists of words, arithmetic such as the serial sevens, language use and comprehension, and basic motor skills. The Higher your score, the higher your function. Scale Ranges from 1-30</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="20" upper_limit="30"/>
                    <measurement group_id="B2" value="30" lower_limit="22" upper_limit="30"/>
                    <measurement group_id="B3" value="29" lower_limit="15" upper_limit="30"/>
                    <measurement group_id="B4" value="29" lower_limit="15" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Steroids</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities (Phase 1)</title>
        <time_frame>cycle 1 - 28 days</time_frame>
        <population>19 patients enrolled in dose escalation but 4 were removed for reasons other than drug related toxicity</population>
        <group_list>
          <group group_id="O1">
            <title>Reporting Group - Phase 1</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. All dose Levels
tandutinib: Given orally
pharmacological study: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities (Phase 1)</title>
          <population>19 patients enrolled in dose escalation but 4 were removed for reasons other than drug related toxicity</population>
          <units>mg BID</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Determine the Tumor/Plasma Ratio of in Subjects With Recurrent GBM Undergoing Resections (Phase 0)</title>
        <description>participants are administered tandutinib (500mg BID) for 7 days prior to surgery and then undergo resection for recurrent glioblastoma. Tissue samples will be collected for correlative studies - determine tumor/plasma ratio.</description>
        <time_frame>7 days prior to surgery including surgery</time_frame>
        <population>a tandutinib tumor:plasma ratio of &gt;/=0.33 was the objective in a minimum of 3/6 subjects in order to proceed with Phase 1/2 study. 6 samples received, but 2 samples were found to be thawed at receipt and not used in analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Feasibility</title>
            <description>Participants receive oral tandutinib 500 mg twice daily for 7 days prior to surgery. Patients then undergo biopsy or surgery to remove the tumor. Tissue collected for tumor/plasma ratio.
Post surgery, within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (not necessary for feasibility)
conventional surgery
oral tandutinib
Pharmacological study
Tissue samples
conventional surgery: Undergo surgery
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Tumor/Plasma Ratio of in Subjects With Recurrent GBM Undergoing Resections (Phase 0)</title>
          <description>participants are administered tandutinib (500mg BID) for 7 days prior to surgery and then undergo resection for recurrent glioblastoma. Tissue samples will be collected for correlative studies - determine tumor/plasma ratio.</description>
          <population>a tandutinib tumor:plasma ratio of &gt;/=0.33 was the objective in a minimum of 3/6 subjects in order to proceed with Phase 1/2 study. 6 samples received, but 2 samples were found to be thawed at receipt and not used in analysis</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Dose Limiting Toxicities Per Dose Level</title>
        <description>cohorts of 3-6 pts will recieve oral tandutinib starting at 500mg BID with a dose escalation in each cohort. Each treatment cycle is 28 days. Evaluation period for MTD is 1st cycle - 28 days.
dose limiting toxicity defined as: grades 3-4 severity (except vomiting and diarrhea without sufficient prophylaxis delay of treatment &gt; 14 days. ANC less/equal 500m/mm3; Plts less/equal 25,000/mm3; febrile neutropenia or delay of treatment &gt; 14 days</description>
        <time_frame>28 days</time_frame>
        <population>all GBM, All prior treatment with RT. assessment was for 28 days, cycle 1. 3 dose levels 500, 600 and 700mg</population>
        <group_list>
          <group group_id="O1">
            <title>Level 1 - 500mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Level 2 - 600mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 600mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Level 3 - 700mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 700mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose Limiting Toxicities Per Dose Level</title>
          <description>cohorts of 3-6 pts will recieve oral tandutinib starting at 500mg BID with a dose escalation in each cohort. Each treatment cycle is 28 days. Evaluation period for MTD is 1st cycle - 28 days.
dose limiting toxicity defined as: grades 3-4 severity (except vomiting and diarrhea without sufficient prophylaxis delay of treatment &gt; 14 days. ANC less/equal 500m/mm3; Plts less/equal 25,000/mm3; febrile neutropenia or delay of treatment &gt; 14 days</description>
          <population>all GBM, All prior treatment with RT. assessment was for 28 days, cycle 1. 3 dose levels 500, 600 and 700mg</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response (Complete Response and Partial Response) Rate (Phase II)</title>
        <description>pts receive a scan baseline and prior to every odd cycle. All responses are centrally reviewed Complete response Complete disappearance of all tumor on MRI scan, off all glucocorticoids with stable or improving neurological exam minimum of 4 wks Partial response Greater than or equal 50% reduction in tumor size on MRI, on sable or decreasing glucocorticoids with stable or improving neurological exam for a minimum of 4 wks.
Progressive disease Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.
Stable disease Clinical status and MRI does not qualify for complete response, partial response or progression</description>
        <time_frame>Up to 4 years</time_frame>
        <population>In the first stage, 31 patients would be enrolled and the trial would be terminated if 3 or fewer patients demonstrated objective responses (partial response or complete response)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 3 - Phase 2</title>
            <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response (Complete Response and Partial Response) Rate (Phase II)</title>
          <description>pts receive a scan baseline and prior to every odd cycle. All responses are centrally reviewed Complete response Complete disappearance of all tumor on MRI scan, off all glucocorticoids with stable or improving neurological exam minimum of 4 wks Partial response Greater than or equal 50% reduction in tumor size on MRI, on sable or decreasing glucocorticoids with stable or improving neurological exam for a minimum of 4 wks.
Progressive disease Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.
Stable disease Clinical status and MRI does not qualify for complete response, partial response or progression</description>
          <population>In the first stage, 31 patients would be enrolled and the trial would be terminated if 3 or fewer patients demonstrated objective responses (partial response or complete response)</population>
          <units>participants with objective response</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (Max Concentration of Plasma) for Tandutinib in Phase 1 and Phase 2</title>
        <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
        <time_frame>28 days</time_frame>
        <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Level 1 - 500mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Level 2 - 600mg BID (Phase 1 &amp; Phase 2)</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
Phase 2: MTD dose Patients receive tandutinib as in phase I at the MTD (600mg BID) determined in phase I.
600mg was the determined MTD in Dose Escalation
dose for tandtinib is 600mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Level 3 - 700mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 700mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Max Concentration of Plasma) for Tandutinib in Phase 1 and Phase 2</title>
          <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
          <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379" spread="193"/>
                    <measurement group_id="O2" value="486" spread="307"/>
                    <measurement group_id="O3" value="1285" spread="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (Apparent Terminal Phase Half-life) for Tandutinib in Phase 1 and Phase 2</title>
        <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
        <time_frame>28 days</time_frame>
        <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Level 1 - 500mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Level 2 - 600mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
Phase 2: MTD dose Patients receive tandutinib as in phase I at the MTD (600mg BID) determined in phase I.
600mg was the determined MTD in Dose Escalation
dose for tandtinib is 600mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Level 3 - 700mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 700mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Apparent Terminal Phase Half-life) for Tandutinib in Phase 1 and Phase 2</title>
          <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
          <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="1.1"/>
                    <measurement group_id="O2" value="10.4" spread="2.5"/>
                    <measurement group_id="O3" value="13.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (Area Under the Plasma Concentration Time Profile From Zero to Infinity (AUC)) for Tandutinib in Phase 1 and Phase 2</title>
        <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
        <time_frame>28 days</time_frame>
        <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Level 1 - 500mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Level 2 - 600mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
Phase 2: MTD dose Patients receive tandutinib as in phase I at the MTD (600mg BID) determined in phase I.
600mg was the determined MTD in Dose Escalation
dose for tandtinib is 600mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Level 3 - 700mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 700mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Area Under the Plasma Concentration Time Profile From Zero to Infinity (AUC)) for Tandutinib in Phase 1 and Phase 2</title>
          <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
          <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
          <units>ng*h/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3961" spread="1414"/>
                    <measurement group_id="O2" value="4659" spread="1926"/>
                    <measurement group_id="O3" value="8193" spread="1915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics; Apparent Oral Clearance for Tandutinib in Phase 1 and Phase 2</title>
        <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
        <time_frame>28 days</time_frame>
        <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Level 1 - 500mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Level 2 - 600mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
Phase 2: MTD dose Patients receive tandutinib as in phase I at the MTD (600mg BID) determined in phase I.
600mg was the determined MTD in Dose Escalation
dose for tandtinib is 600mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Level 3 - 700mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 700mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics; Apparent Oral Clearance for Tandutinib in Phase 1 and Phase 2</title>
          <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
          <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post surgery</population>
          <units>L/h</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="45"/>
                    <measurement group_id="O2" value="129" spread="54"/>
                    <measurement group_id="O3" value="85" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics; Apparent Oral Total Body Volume of Distribution for Tandutinib in Phase 1 and Phase 2</title>
        <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
        <time_frame>28 days</time_frame>
        <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Level 1 - 500mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Level 2 - 600mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
Phase 2: MTD dose Patients receive tandutinib as in phase I at the MTD (600mg BID) determined in phase I.
600mg was the determined MTD in Dose Escalation
dose for tandtinib is 600mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Level 3 - 700mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 700mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics; Apparent Oral Total Body Volume of Distribution for Tandutinib in Phase 1 and Phase 2</title>
          <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
          <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
          <units>L</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2386" spread="934"/>
                    <measurement group_id="O2" value="1987" spread="1102"/>
                    <measurement group_id="O3" value="1764" spread="1242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics; Steady-state Trough Concentration for Tandutinib in Phase 1 and Phase 2</title>
        <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
        <time_frame>28 days</time_frame>
        <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Level 1 - 500mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O2">
            <title>Level 2 - 600mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
Phase 2: MTD dose Patients receive tandutinib as in phase I at the MTD (600mg BID) determined in phase I.
600mg was the determined MTD in Dose Escalation
dose for tandtinib is 600mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
          <group group_id="O3">
            <title>Level 3 - 700mg BID</title>
            <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
dose for tandtinib is 700mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics; Steady-state Trough Concentration for Tandutinib in Phase 1 and Phase 2</title>
          <description>pre-dose, 1,2,4,6,8 and 24 hrs post dose and days 8,15, 21 of cycle 1 and day one of cycle 2</description>
          <population>56 enrolled pts, 40 evaluable PK sample sets, parameters not estimated for 16 pts. (Sample collected after next dose taken 3pts;1st dose given before collecting redose sample 1 pt; concentration sample 24h after dosing &lt;LOQ 8 pts or samples not collected proper times 1pt. 2pts feasibility arm did not restart treatment post-surgery</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518" spread="182"/>
                    <measurement group_id="O2" value="582" spread="381"/>
                    <measurement group_id="O3" value="971" spread="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Phase II)</title>
        <description>Median time of survival along with 95% confidence interval will be estimated using Kaplan-Meier method. An overall failure rate will be estimated with 95% CI.</description>
        <time_frame>Up to 4 years</time_frame>
        <population>Median time of survival along with 95% confidence interval will be estimated using Kaplan-Meier method. An overall failure rate will be estimated with 95% CI. The overall failure rate is expressed as hazard of failure per person-year of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 3 - Phase 2</title>
            <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Phase II)</title>
          <description>Median time of survival along with 95% confidence interval will be estimated using Kaplan-Meier method. An overall failure rate will be estimated with 95% CI.</description>
          <population>Median time of survival along with 95% confidence interval will be estimated using Kaplan-Meier method. An overall failure rate will be estimated with 95% CI. The overall failure rate is expressed as hazard of failure per person-year of follow-up.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="5.9" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six-month Progression-free Survival Rate (Phase II)</title>
        <description>The probability of 6-momth progression-free survival will be estimated using binomial distribution.
Progression defined as: Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.</description>
        <time_frame>At 6 months</time_frame>
        <population>The probability of 6-momth progression-free survival will be estimated using binomial distribution.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 3 - Phase 2</title>
            <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Six-month Progression-free Survival Rate (Phase II)</title>
          <description>The probability of 6-momth progression-free survival will be estimated using binomial distribution.
Progression defined as: Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.</description>
          <population>The probability of 6-momth progression-free survival will be estimated using binomial distribution.</population>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="6" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Failure Rate (Phase II)</title>
        <description>The overall failure rate is expressed as hazard of failure per person-year of follow-up.</description>
        <time_frame>up to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 3 - Phase 2</title>
            <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Failure Rate (Phase II)</title>
          <description>The overall failure rate is expressed as hazard of failure per person-year of follow-up.</description>
          <units>failure per person-year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.57" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Serious or Life Threatening Toxicities</title>
        <description>Grade 3 or 4 toxicities related to treatment as determined by the CTCAE</description>
        <time_frame>2 year period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 3 - Phase 2</title>
            <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Serious or Life Threatening Toxicities</title>
          <description>Grade 3 or 4 toxicities related to treatment as determined by the CTCAE</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Protein Expression Patterns Post Treatment - Loss or Gain</title>
        <description>serial blood samples over multiple time points (prior to treatment, 2 days post treatment, 8 days post treatment, 10 days post treatment and 28 days post treatment.
statistical analyses presented for the comparisons that yielded a p-value &lt;=0.05</description>
        <time_frame>baseline - cycle 2 (28 days)</time_frame>
        <population>peripheral blood was obtained from 20 patients enrolled in the phase 2 portion of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline (BL) - Overall Survival (OS)</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O2">
            <title>Baseline (BL) - Progression Free Survival (PFS)</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O3">
            <title>Association Between OS and Biomarker Day 2 / BL</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O4">
            <title>Association Between PFS Biomarker Day 2 / BL</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O5">
            <title>Association Between OS and Biomarker Day 8 / BL</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O6">
            <title>Association Between PFS Biomarker Day 8 / BL</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O7">
            <title>Association Between OS and Biomarker Day 10 /BL</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O8">
            <title>Association Between PFS Biomarker Day 10 / BL</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O9">
            <title>Association Between OS and Biomarker Day 28 / BL</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
          <group group_id="O10">
            <title>Association Between PFS Biomarker Day 28 / BL</title>
            <description>Patients receive tandutinib at 600mg as was the determined MTD in Dose Escalation
oral tandutinib
tandutinib: Given orally
pharmacological study: Correlative studies
Peripheral blood</description>
          </group>
        </group_list>
        <measure>
          <title>Protein Expression Patterns Post Treatment - Loss or Gain</title>
          <description>serial blood samples over multiple time points (prior to treatment, 2 days post treatment, 8 days post treatment, 10 days post treatment and 28 days post treatment.
statistical analyses presented for the comparisons that yielded a p-value &lt;=0.05</description>
          <population>peripheral blood was obtained from 20 patients enrolled in the phase 2 portion of the study.</population>
          <units>hazard ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SDF_1a</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.01" lower_limit="0" upper_limit="1.8"/>
                    <measurement group_id="O4" value="0.14" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O5" value="0.83" lower_limit="0.01" upper_limit="62"/>
                    <measurement group_id="O6" value="0.08" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O7" value="1.4" lower_limit="0" upper_limit="2531"/>
                    <measurement group_id="O8" value="1.68" lower_limit="0" upper_limit="3976"/>
                    <measurement group_id="O9" value="0.18" lower_limit="0" upper_limit="8.42"/>
                    <measurement group_id="O10" value="0.76" lower_limit="0.02" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bFGF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="14"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.99" upper_limit="1.01"/>
                    <measurement group_id="O2" value="1.01" lower_limit="1.00" upper_limit="1.02"/>
                    <measurement group_id="O3" value="0.72" lower_limit="0.42" upper_limit="1.23"/>
                    <measurement group_id="O4" value="0.52" lower_limit="0.27" upper_limit="1.04"/>
                    <measurement group_id="O5" value="1.03" lower_limit="0.61" upper_limit="1.74"/>
                    <measurement group_id="O6" value="0.88" lower_limit="0.53" upper_limit="1.47"/>
                    <measurement group_id="O7" value="0.65" lower_limit="0.36" upper_limit="1.17"/>
                    <measurement group_id="O8" value="0.60" lower_limit="0.31" upper_limit="1.14"/>
                    <measurement group_id="O9" value="0.84" lower_limit="0.44" upper_limit="1.61"/>
                    <measurement group_id="O10" value="0.70" lower_limit="0.37" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIGF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="14"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.99" upper_limit="1.01"/>
                    <measurement group_id="O2" value="1.01" lower_limit="1.00" upper_limit="1.02"/>
                    <measurement group_id="O3" value="8.56" lower_limit="0.16" upper_limit="449"/>
                    <measurement group_id="O4" value="1.53" lower_limit="0.01" upper_limit="197"/>
                    <measurement group_id="O5" value="3.76" lower_limit="0.55" upper_limit="26"/>
                    <measurement group_id="O6" value="11.8" lower_limit="1.08" upper_limit="129"/>
                    <measurement group_id="O7" value="0.91" lower_limit="0.03" upper_limit="27"/>
                    <measurement group_id="O8" value="0.69" lower_limit="0.02" upper_limit="22"/>
                    <measurement group_id="O9" value="1.18" lower_limit="0.03" upper_limit="55"/>
                    <measurement group_id="O10" value="6.24" lower_limit="0.07" upper_limit="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sFLT_1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="14"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.08" lower_limit="0.08" upper_limit="1.45"/>
                    <measurement group_id="O4" value="1.22" lower_limit="0.89" upper_limit="1.66"/>
                    <measurement group_id="O5" value="1.03" lower_limit="0.86" upper_limit="1.23"/>
                    <measurement group_id="O6" value="1.12" lower_limit="0.92" upper_limit="1.36"/>
                    <measurement group_id="O7" value="1.06" lower_limit="0.08" upper_limit="1.41"/>
                    <measurement group_id="O8" value="1.13" lower_limit="0.82" upper_limit="1.55"/>
                    <measurement group_id="O9" value="61.5" lower_limit="1" upper_limit="3774"/>
                    <measurement group_id="O10" value="524" lower_limit="4" upper_limit="71128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="14"/>
                    <count group_id="O10" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.55" lower_limit="0.07" upper_limit="4.1"/>
                    <measurement group_id="O4" value="0.71" lower_limit="0.12" upper_limit="4.14"/>
                    <measurement group_id="O5" value="0.43" lower_limit="0.08" upper_limit="2.37"/>
                    <measurement group_id="O6" value="0.31" lower_limit="0.05" upper_limit="1.85"/>
                    <measurement group_id="O7" value="0.88" lower_limit="0.34" upper_limit="2.26"/>
                    <measurement group_id="O8" value="0.74" lower_limit="0.33" upper_limit="1.62"/>
                    <measurement group_id="O9" value="1.11" lower_limit="0.17" upper_limit="7.35"/>
                    <measurement group_id="O10" value="1.67" lower_limit="0.2" upper_limit="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAIX</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="11"/>
                    <count group_id="O9" value="12"/>
                    <count group_id="O10" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.01"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.16" lower_limit="0.23" upper_limit="5.85"/>
                    <measurement group_id="O4" value="0.38" lower_limit="0.05" upper_limit="3.19"/>
                    <measurement group_id="O5" value="1.53" lower_limit="0.99" upper_limit="2.36"/>
                    <measurement group_id="O6" value="1.74" lower_limit="1.11" upper_limit="2.72"/>
                    <measurement group_id="O7" value="1.24" lower_limit="0.76" upper_limit="2.01"/>
                    <measurement group_id="O8" value="0.80" lower_limit="0.44" upper_limit="1.45"/>
                    <measurement group_id="O9" value="1.41" lower_limit="0.83" upper_limit="2.41"/>
                    <measurement group_id="O10" value="0.89" lower_limit="0.53" upper_limit="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGFR2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="12"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.32" lower_limit="0.01" upper_limit="13.9"/>
                    <measurement group_id="O4" value="0.74" lower_limit="0.02" upper_limit="31"/>
                    <measurement group_id="O5" value="2.02" lower_limit="0.07" upper_limit="62"/>
                    <measurement group_id="O6" value="0.65" lower_limit="0.02" upper_limit="17.3"/>
                    <measurement group_id="O7" value="0.10" lower_limit="0" upper_limit="70"/>
                    <measurement group_id="O8" value="0.27" lower_limit="0" upper_limit="30"/>
                    <measurement group_id="O9" value="0.001" lower_limit="0" upper_limit="1.18"/>
                    <measurement group_id="O10" value="0.001" lower_limit="0" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ANG_2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="12"/>
                    <count group_id="O9" value="13"/>
                    <count group_id="O10" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.54" lower_limit="0.04" upper_limit="7.42"/>
                    <measurement group_id="O4" value="2.15" lower_limit="0.14" upper_limit="33"/>
                    <measurement group_id="O5" value="0.89" lower_limit="0.30" upper_limit="2.68"/>
                    <measurement group_id="O6" value="1.12" lower_limit="0.31" upper_limit="4.09"/>
                    <measurement group_id="O7" value="0.55" lower_limit="0.13" upper_limit="2.36"/>
                    <measurement group_id="O8" value="1.05" lower_limit="0.26" upper_limit="4.19"/>
                    <measurement group_id="O9" value="0.43" lower_limit="0.06" upper_limit="2.91"/>
                    <measurement group_id="O10" value="0.52" lower_limit="0.05" upper_limit="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>VEGFR2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>PIGF</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>CAIX</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>sFLT_1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>sFLT_1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Regression, Cox</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>VEGFR2</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of first dose until patient went off treatment. &lt;4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I - Feasibility</title>
          <description>Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
conventional surgery
oral tandutinib
Pharmacological study
Tissue samples
conventional surgery: Undergo surgery
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm 2 - Dose Escalation (Phase 1)</title>
          <description>Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
the starting dose for tandtinib is 500mg BID
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
        </group>
        <group group_id="E3">
          <title>Arm 3 - Phase 2</title>
          <description>Patients receive tandutinib as in phase I at the MTD determined in phase I.
600mg was the determined MTD in Dose Escalation
oral tandutinib
Pharmacological study
Tissue samples
tandutinib: Given orally
pharmacological study: Correlative studies
Tissue samples: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (3.0)">diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (3.0)">confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="19" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" events="74" subjects_affected="11" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" events="19" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E3" events="37" subjects_affected="19" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E3" events="26" subjects_affected="19" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (3.0)">fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>edema face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>edema limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decrease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="20" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="23" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E3" events="23" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" events="45" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>blood bilirubin increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>neutrophil count decrease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="12" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" events="37" subjects_affected="15" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="13" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>generalized muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash maculopapular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Simon's two-stage design Phase 2, prespecified goal patients alive &amp; progression-free survival 6-months not achieved first stage, 2nd stage not done &amp; trial closed/stopped.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Stuart A Grossman, MD Director of ABTC</name_or_title>
      <organization>Adult Brain Tumor Consortium</organization>
      <phone>410-955-8837</phone>
      <email>grossman@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

